开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=2216670, encodeId=ffff22166e0d9, content=投稿命中率:25.0 经验分享：提交后整整两个半月编辑才拒稿，甚至没有进入peer review，太慢了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62599117691, createdName=ms3000001317887892, createdTime=Wed Jul 24 17:47:12 CST 2024, time=2024-07-24, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2214332, encodeId=be462214332c9, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：非常严谨的刊。第一轮两个月给小修，因为年末开题等事情冲突申请延期，小修回去后再次二次返修：小修。审稿人很专业，是专门做这方面的，每次都会提一些看似不多，但其实比较麻烦的审稿意见。中间因自己原因两次推迟返修，总时间花费8个月中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c928304496, createdName=ms6000000052163793, createdTime=Wed Jul 10 23:30:34 CST 2024, time=2024-07-10, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2174200, encodeId=c61f21e4200e6, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：Copd;呼吸 经验分享：2023–5月投，12月二审，临床评审非常nice,统计是，评审非常专业，非常细致，第一次12个问题，9个全统计，第二次三个不同的统计问题，附件里面的包括学历年限需要标注，还有一些公共问题，我把北爱儿兰当作英国的，被告知是独立国家。但愿一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b945427479, createdName=ms3000000140014381, createdTime=Mon Dec 11 09:22:52 CST 2023, time=2023-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238853, encodeId=7ead12388534a, content=偏重的研究方向：呼吸系统疾病;膀胱癌 经验分享：2022/08/15上午提交稿件 2022/08/15下午2点编辑返回，要求修改格式 2022/08/15下午6点就显示in peer review 不知道是不是真的送外审了，继续更新吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210319/09cc2ef1a3ce4358b3a0b674a1148d18/0249c77562784ebb9c835e8c16aef5aa.jpg, createdBy=44ed5456069, createdName=ElSolAzul, createdTime=Mon Aug 15 18:24:26 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233241, encodeId=d155123324187, content=好像还没人，先记录一下投稿过程吧在这： 2022/7/17: 投稿 2022/7/18: 编辑返回，要求修改；修改后重新提交 2022/7/18: 重新提交后当天In Peer Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220615/578dba9b787c425badc007604abaa5db/9fb1b073f8a243c9bd6e15325269f925.jpg, createdBy=15245410727, createdName=年年有余的余, createdTime=Mon Jul 18 18:25:02 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113953, encodeId=4ed6111395384, content=讨论中一般可以讨论什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=465, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113954, encodeId=8ed211139544a, content=讨论中我和之前发表文章结果不一致怎么处理？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=642, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2024-07-24 ms3000001317887892 来自加利福尼亚

投稿命中率:25.0
经验分享：提交后整整两个半月编辑才拒稿，甚至没有进入peer review，太慢了。。。。

52 0

[GetPortalCommentsPageByObjectIdResponse(id=2216670, encodeId=ffff22166e0d9, content=投稿命中率:25.0 经验分享：提交后整整两个半月编辑才拒稿，甚至没有进入peer review，太慢了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62599117691, createdName=ms3000001317887892, createdTime=Wed Jul 24 17:47:12 CST 2024, time=2024-07-24, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2214332, encodeId=be462214332c9, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：非常严谨的刊。第一轮两个月给小修，因为年末开题等事情冲突申请延期，小修回去后再次二次返修：小修。审稿人很专业，是专门做这方面的，每次都会提一些看似不多，但其实比较麻烦的审稿意见。中间因自己原因两次推迟返修，总时间花费8个月中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c928304496, createdName=ms6000000052163793, createdTime=Wed Jul 10 23:30:34 CST 2024, time=2024-07-10, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2174200, encodeId=c61f21e4200e6, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：Copd;呼吸 经验分享：2023–5月投，12月二审，临床评审非常nice,统计是，评审非常专业，非常细致，第一次12个问题，9个全统计，第二次三个不同的统计问题，附件里面的包括学历年限需要标注，还有一些公共问题，我把北爱儿兰当作英国的，被告知是独立国家。但愿一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b945427479, createdName=ms3000000140014381, createdTime=Mon Dec 11 09:22:52 CST 2023, time=2023-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238853, encodeId=7ead12388534a, content=偏重的研究方向：呼吸系统疾病;膀胱癌 经验分享：2022/08/15上午提交稿件 2022/08/15下午2点编辑返回，要求修改格式 2022/08/15下午6点就显示in peer review 不知道是不是真的送外审了，继续更新吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210319/09cc2ef1a3ce4358b3a0b674a1148d18/0249c77562784ebb9c835e8c16aef5aa.jpg, createdBy=44ed5456069, createdName=ElSolAzul, createdTime=Mon Aug 15 18:24:26 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233241, encodeId=d155123324187, content=好像还没人，先记录一下投稿过程吧在这： 2022/7/17: 投稿 2022/7/18: 编辑返回，要求修改；修改后重新提交 2022/7/18: 重新提交后当天In Peer Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220615/578dba9b787c425badc007604abaa5db/9fb1b073f8a243c9bd6e15325269f925.jpg, createdBy=15245410727, createdName=年年有余的余, createdTime=Mon Jul 18 18:25:02 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113953, encodeId=4ed6111395384, content=讨论中一般可以讨论什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=465, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113954, encodeId=8ed211139544a, content=讨论中我和之前发表文章结果不一致怎么处理？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=642, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2024-07-10 ms6000000052163793 来自湖南省

审稿速度:2.0 | 投稿命中率:50.0
经验分享：非常严谨的刊。第一轮两个月给小修，因为年末开题等事情冲突申请延期，小修回去后再次二次返修：小修。审稿人很专业，是专门做这方面的，每次都会提一些看似不多，但其实比较麻烦的审稿意见。中间因自己原因两次推迟返修，总时间花费8个月中。

73 0

[GetPortalCommentsPageByObjectIdResponse(id=2216670, encodeId=ffff22166e0d9, content=投稿命中率:25.0 经验分享：提交后整整两个半月编辑才拒稿，甚至没有进入peer review，太慢了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62599117691, createdName=ms3000001317887892, createdTime=Wed Jul 24 17:47:12 CST 2024, time=2024-07-24, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2214332, encodeId=be462214332c9, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：非常严谨的刊。第一轮两个月给小修，因为年末开题等事情冲突申请延期，小修回去后再次二次返修：小修。审稿人很专业，是专门做这方面的，每次都会提一些看似不多，但其实比较麻烦的审稿意见。中间因自己原因两次推迟返修，总时间花费8个月中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c928304496, createdName=ms6000000052163793, createdTime=Wed Jul 10 23:30:34 CST 2024, time=2024-07-10, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2174200, encodeId=c61f21e4200e6, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：Copd;呼吸 经验分享：2023–5月投，12月二审，临床评审非常nice,统计是，评审非常专业，非常细致，第一次12个问题，9个全统计，第二次三个不同的统计问题，附件里面的包括学历年限需要标注，还有一些公共问题，我把北爱儿兰当作英国的，被告知是独立国家。但愿一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b945427479, createdName=ms3000000140014381, createdTime=Mon Dec 11 09:22:52 CST 2023, time=2023-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238853, encodeId=7ead12388534a, content=偏重的研究方向：呼吸系统疾病;膀胱癌 经验分享：2022/08/15上午提交稿件 2022/08/15下午2点编辑返回，要求修改格式 2022/08/15下午6点就显示in peer review 不知道是不是真的送外审了，继续更新吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210319/09cc2ef1a3ce4358b3a0b674a1148d18/0249c77562784ebb9c835e8c16aef5aa.jpg, createdBy=44ed5456069, createdName=ElSolAzul, createdTime=Mon Aug 15 18:24:26 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233241, encodeId=d155123324187, content=好像还没人，先记录一下投稿过程吧在这： 2022/7/17: 投稿 2022/7/18: 编辑返回，要求修改；修改后重新提交 2022/7/18: 重新提交后当天In Peer Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220615/578dba9b787c425badc007604abaa5db/9fb1b073f8a243c9bd6e15325269f925.jpg, createdBy=15245410727, createdName=年年有余的余, createdTime=Mon Jul 18 18:25:02 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113953, encodeId=4ed6111395384, content=讨论中一般可以讨论什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=465, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113954, encodeId=8ed211139544a, content=讨论中我和之前发表文章结果不一致怎么处理？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=642, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2023-12-11 ms3000000140014381

审稿速度:12.0 | 投稿命中率:25.0
偏重的研究方向：Copd;呼吸
经验分享：2023–5月投，12月二审，临床评审非常nice,统计是，评审非常专业，非常细致，第一次12个问题，9个全统计，第二次三个不同的统计问题，附件里面的包括学历年限需要标注，还有一些公共问题，我把北爱儿兰当作英国的，被告知是独立国家。但愿一切顺利

96 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2216670, encodeId=ffff22166e0d9, content=投稿命中率:25.0 经验分享：提交后整整两个半月编辑才拒稿，甚至没有进入peer review，太慢了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62599117691, createdName=ms3000001317887892, createdTime=Wed Jul 24 17:47:12 CST 2024, time=2024-07-24, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2214332, encodeId=be462214332c9, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：非常严谨的刊。第一轮两个月给小修，因为年末开题等事情冲突申请延期，小修回去后再次二次返修：小修。审稿人很专业，是专门做这方面的，每次都会提一些看似不多，但其实比较麻烦的审稿意见。中间因自己原因两次推迟返修，总时间花费8个月中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c928304496, createdName=ms6000000052163793, createdTime=Wed Jul 10 23:30:34 CST 2024, time=2024-07-10, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2174200, encodeId=c61f21e4200e6, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：Copd;呼吸 经验分享：2023–5月投，12月二审，临床评审非常nice,统计是，评审非常专业，非常细致，第一次12个问题，9个全统计，第二次三个不同的统计问题，附件里面的包括学历年限需要标注，还有一些公共问题，我把北爱儿兰当作英国的，被告知是独立国家。但愿一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b945427479, createdName=ms3000000140014381, createdTime=Mon Dec 11 09:22:52 CST 2023, time=2023-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238853, encodeId=7ead12388534a, content=偏重的研究方向：呼吸系统疾病;膀胱癌 经验分享：2022/08/15上午提交稿件 2022/08/15下午2点编辑返回，要求修改格式 2022/08/15下午6点就显示in peer review 不知道是不是真的送外审了，继续更新吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210319/09cc2ef1a3ce4358b3a0b674a1148d18/0249c77562784ebb9c835e8c16aef5aa.jpg, createdBy=44ed5456069, createdName=ElSolAzul, createdTime=Mon Aug 15 18:24:26 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233241, encodeId=d155123324187, content=好像还没人，先记录一下投稿过程吧在这： 2022/7/17: 投稿 2022/7/18: 编辑返回，要求修改；修改后重新提交 2022/7/18: 重新提交后当天In Peer Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220615/578dba9b787c425badc007604abaa5db/9fb1b073f8a243c9bd6e15325269f925.jpg, createdBy=15245410727, createdName=年年有余的余, createdTime=Mon Jul 18 18:25:02 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113953, encodeId=4ed6111395384, content=讨论中一般可以讨论什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=465, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113954, encodeId=8ed211139544a, content=讨论中我和之前发表文章结果不一致怎么处理？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=642, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2022-08-15 ElSolAzul

偏重的研究方向：呼吸系统疾病;膀胱癌
经验分享：2022/08/15上午提交稿件
2022/08/15下午2点编辑返回，要求修改格式
2022/08/15下午6点就显示in peer review
不知道是不是真的送外审了，继续更新吧

218 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2216670, encodeId=ffff22166e0d9, content=投稿命中率:25.0 经验分享：提交后整整两个半月编辑才拒稿，甚至没有进入peer review，太慢了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62599117691, createdName=ms3000001317887892, createdTime=Wed Jul 24 17:47:12 CST 2024, time=2024-07-24, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2214332, encodeId=be462214332c9, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：非常严谨的刊。第一轮两个月给小修，因为年末开题等事情冲突申请延期，小修回去后再次二次返修：小修。审稿人很专业，是专门做这方面的，每次都会提一些看似不多，但其实比较麻烦的审稿意见。中间因自己原因两次推迟返修，总时间花费8个月中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c928304496, createdName=ms6000000052163793, createdTime=Wed Jul 10 23:30:34 CST 2024, time=2024-07-10, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2174200, encodeId=c61f21e4200e6, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：Copd;呼吸 经验分享：2023–5月投，12月二审，临床评审非常nice,统计是，评审非常专业，非常细致，第一次12个问题，9个全统计，第二次三个不同的统计问题，附件里面的包括学历年限需要标注，还有一些公共问题，我把北爱儿兰当作英国的，被告知是独立国家。但愿一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b945427479, createdName=ms3000000140014381, createdTime=Mon Dec 11 09:22:52 CST 2023, time=2023-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238853, encodeId=7ead12388534a, content=偏重的研究方向：呼吸系统疾病;膀胱癌 经验分享：2022/08/15上午提交稿件 2022/08/15下午2点编辑返回，要求修改格式 2022/08/15下午6点就显示in peer review 不知道是不是真的送外审了，继续更新吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210319/09cc2ef1a3ce4358b3a0b674a1148d18/0249c77562784ebb9c835e8c16aef5aa.jpg, createdBy=44ed5456069, createdName=ElSolAzul, createdTime=Mon Aug 15 18:24:26 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233241, encodeId=d155123324187, content=好像还没人，先记录一下投稿过程吧在这： 2022/7/17: 投稿 2022/7/18: 编辑返回，要求修改；修改后重新提交 2022/7/18: 重新提交后当天In Peer Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220615/578dba9b787c425badc007604abaa5db/9fb1b073f8a243c9bd6e15325269f925.jpg, createdBy=15245410727, createdName=年年有余的余, createdTime=Mon Jul 18 18:25:02 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113953, encodeId=4ed6111395384, content=讨论中一般可以讨论什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=465, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113954, encodeId=8ed211139544a, content=讨论中我和之前发表文章结果不一致怎么处理？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=642, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2022-07-18 年年有余的余

好像还没人，先记录一下投稿过程吧在这：
2022/7/17: 投稿
2022/7/18: 编辑返回，要求修改；修改后重新提交
2022/7/18: 重新提交后当天In Peer Review

290 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2216670, encodeId=ffff22166e0d9, content=投稿命中率:25.0 经验分享：提交后整整两个半月编辑才拒稿，甚至没有进入peer review，太慢了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62599117691, createdName=ms3000001317887892, createdTime=Wed Jul 24 17:47:12 CST 2024, time=2024-07-24, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2214332, encodeId=be462214332c9, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：非常严谨的刊。第一轮两个月给小修，因为年末开题等事情冲突申请延期，小修回去后再次二次返修：小修。审稿人很专业，是专门做这方面的，每次都会提一些看似不多，但其实比较麻烦的审稿意见。中间因自己原因两次推迟返修，总时间花费8个月中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c928304496, createdName=ms6000000052163793, createdTime=Wed Jul 10 23:30:34 CST 2024, time=2024-07-10, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2174200, encodeId=c61f21e4200e6, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：Copd;呼吸 经验分享：2023–5月投，12月二审，临床评审非常nice,统计是，评审非常专业，非常细致，第一次12个问题，9个全统计，第二次三个不同的统计问题，附件里面的包括学历年限需要标注，还有一些公共问题，我把北爱儿兰当作英国的，被告知是独立国家。但愿一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b945427479, createdName=ms3000000140014381, createdTime=Mon Dec 11 09:22:52 CST 2023, time=2023-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238853, encodeId=7ead12388534a, content=偏重的研究方向：呼吸系统疾病;膀胱癌 经验分享：2022/08/15上午提交稿件 2022/08/15下午2点编辑返回，要求修改格式 2022/08/15下午6点就显示in peer review 不知道是不是真的送外审了，继续更新吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210319/09cc2ef1a3ce4358b3a0b674a1148d18/0249c77562784ebb9c835e8c16aef5aa.jpg, createdBy=44ed5456069, createdName=ElSolAzul, createdTime=Mon Aug 15 18:24:26 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233241, encodeId=d155123324187, content=好像还没人，先记录一下投稿过程吧在这： 2022/7/17: 投稿 2022/7/18: 编辑返回，要求修改；修改后重新提交 2022/7/18: 重新提交后当天In Peer Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220615/578dba9b787c425badc007604abaa5db/9fb1b073f8a243c9bd6e15325269f925.jpg, createdBy=15245410727, createdName=年年有余的余, createdTime=Mon Jul 18 18:25:02 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113953, encodeId=4ed6111395384, content=讨论中一般可以讨论什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=465, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113954, encodeId=8ed211139544a, content=讨论中我和之前发表文章结果不一致怎么处理？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=642, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2021-12-28 msSSSSSD

讨论中一般可以讨论什么？

465 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2216670, encodeId=ffff22166e0d9, content=投稿命中率:25.0 经验分享：提交后整整两个半月编辑才拒稿，甚至没有进入peer review，太慢了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62599117691, createdName=ms3000001317887892, createdTime=Wed Jul 24 17:47:12 CST 2024, time=2024-07-24, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2214332, encodeId=be462214332c9, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：非常严谨的刊。第一轮两个月给小修，因为年末开题等事情冲突申请延期，小修回去后再次二次返修：小修。审稿人很专业，是专门做这方面的，每次都会提一些看似不多，但其实比较麻烦的审稿意见。中间因自己原因两次推迟返修，总时间花费8个月中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c928304496, createdName=ms6000000052163793, createdTime=Wed Jul 10 23:30:34 CST 2024, time=2024-07-10, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2174200, encodeId=c61f21e4200e6, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：Copd;呼吸 经验分享：2023–5月投，12月二审，临床评审非常nice,统计是，评审非常专业，非常细致，第一次12个问题，9个全统计，第二次三个不同的统计问题，附件里面的包括学历年限需要标注，还有一些公共问题，我把北爱儿兰当作英国的，被告知是独立国家。但愿一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b945427479, createdName=ms3000000140014381, createdTime=Mon Dec 11 09:22:52 CST 2023, time=2023-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238853, encodeId=7ead12388534a, content=偏重的研究方向：呼吸系统疾病;膀胱癌 经验分享：2022/08/15上午提交稿件 2022/08/15下午2点编辑返回，要求修改格式 2022/08/15下午6点就显示in peer review 不知道是不是真的送外审了，继续更新吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210319/09cc2ef1a3ce4358b3a0b674a1148d18/0249c77562784ebb9c835e8c16aef5aa.jpg, createdBy=44ed5456069, createdName=ElSolAzul, createdTime=Mon Aug 15 18:24:26 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233241, encodeId=d155123324187, content=好像还没人，先记录一下投稿过程吧在这： 2022/7/17: 投稿 2022/7/18: 编辑返回，要求修改；修改后重新提交 2022/7/18: 重新提交后当天In Peer Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220615/578dba9b787c425badc007604abaa5db/9fb1b073f8a243c9bd6e15325269f925.jpg, createdBy=15245410727, createdName=年年有余的余, createdTime=Mon Jul 18 18:25:02 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113953, encodeId=4ed6111395384, content=讨论中一般可以讨论什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=465, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113954, encodeId=8ed211139544a, content=讨论中我和之前发表文章结果不一致怎么处理？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=642, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2021-12-28 小动量

讨论中我和之前发表文章结果不一致怎么处理？

642 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务